These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25566194)

  • 1. IGF-IR Targeted Therapy: Past, Present and Future.
    Janssen JA; Varewijck AJ
    Front Endocrinol (Lausanne); 2014; 5():224. PubMed ID: 25566194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.
    Byron SA; Horwitz KB; Richer JK; Lange CA; Zhang X; Yee D
    Br J Cancer; 2006 Nov; 95(9):1220-8. PubMed ID: 17043687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells.
    Guvakova MA; Surmacz E
    Cancer Res; 1997 Jul; 57(13):2606-10. PubMed ID: 9205064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology.
    Gao J; Chang YS; Jallal B; Viner J
    Cancer Res; 2012 Jan; 72(1):3-12. PubMed ID: 22215692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I.
    Auclair M; Vigouroux C; Desbois-Mouthon C; Deibener J; Kaminski P; Lascols O; Cherqui G; Capeau J; Caron M
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3197-206. PubMed ID: 10487687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
    Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
    Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors.
    Denley A; Carroll JM; Brierley GV; Cosgrove L; Wallace J; Forbes B; Roberts CT
    Mol Cell Biol; 2007 May; 27(10):3569-77. PubMed ID: 17325037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin analogs and cancer: a note of caution.
    Janssen JA; Varewijck AJ
    Front Endocrinol (Lausanne); 2014; 5():79. PubMed ID: 24904529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
    Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
    Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
    Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.
    Vella V; Nicolosi ML; Giuliano S; Bellomo M; Belfiore A; Malaguarnera R
    Front Endocrinol (Lausanne); 2017; 8():31. PubMed ID: 28275367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
    Buck E; Mulvihill M
    Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.
    Surmacz E
    Oncogene; 2003 Sep; 22(42):6589-97. PubMed ID: 14528284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
    Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential signaling activation by insulin and insulin-like growth factors I and II upon binding to insulin receptor isoform A.
    Sacco A; Morcavallo A; Pandini G; Vigneri R; Belfiore A
    Endocrinology; 2009 Aug; 150(8):3594-602. PubMed ID: 19443570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.